NCT03877926: A reported trial by Emergent BioSolutions
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03877926 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 11, 2019 |
| Completion date | Aug. 6, 2020 |
| Required reporting date | Aug. 6, 2021, midnight |
| Actual reporting date | July 8, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |